ACTON, Mass. — February 20, 2026 — Leads & Copy — Bluejay Diagnostics (NASDAQ: BJDX) announced the full exercise of all prefunded warrants issued in its October 2025 private placement as of February 19, 2026.
The company now has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, Bluejay Diagnostics now has approximately 972,000 shares of common stock outstanding.
The company also has cash exercisable warrants outstanding for roughly 1.5 million shares, all with a cash exercise price of $7.00 or greater per share.
Bluejay Diagnostics noted that several recent Schedule 13G filings made by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026. Investors reading such filings should be aware that current beneficial ownership share amounts may therefore be significantly less than the number of shares reflected in such reports, given that these reports show holdings and total shares outstanding on a pre-split basis, notwithstanding that such reports were filed after consummation of the 1-for-4 reverse stock split.
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and the company will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions.
Source: Bluejay Diagnostics
